ATTR-CM – Medxy AI

Vutrisiran Redefines the Therapeutic Landscape for Transthyretin Amyloidosis with Cardiomyopathy: Comprehensive Insights from the HELIOS-B Trial

By MedXY 12/25/2025

The HELIOS-B trial demonstrates that vutrisiran significantly improves clinical outcomes, stabilizes cardiac biomarkers, preserves cardiac structure, and enhances the quality of life in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

Cardiology news

Coramitug Significantly Reduces NT-proBNP in Transthyretin Amyloid Cardiomyopathy: Phase 2 Trial Results

By MedXY 12/25/2025

A Phase 2 randomized trial shows that coramitug, a monoclonal antibody targeting misfolded transthyretin, significantly reduced NT-proBNP levels by 48% in patients with ATTR-CM. While functional outcomes remained stable over 52 weeks, the results suggest a breakthrough in active amyloid clearance.

AI Cardiology news

AI-Augmented Screening Triples Detection Yield of Transthyretin Cardiac Amyloidosis in a Multisite Real-World Trial

By MedXY 11/18/2025

An AI-driven screening program (ATTRACTnet) applied to ECG, echocardiography, demographics and orthopedic history substantially increased case detection of transthyretin cardiac amyloidosis (ATTR‑CM) and led to rapid treatment initiation in a target population.

Cardiology news Specialties

Vutrisiran’s Impact on Cardiac Function and Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights from HELIOS-B

By MedXY 08/17/2025

Vutrisiran improves cardiac structure, function, and biomarkers, reducing mortality and cardiovascular events in transthyretin amyloid cardiomyopathy over 30 months.